Michael Mee
CEO
John Griffin
CTO
Kelly-Anne Pike
SVP Head of R&D
Vincent Frappier
Head of Computational Biology
OUR APPROACH
Turning novel target biology into actionable drug discovery programs.
RIME screens large libraries of AI-designed probes against 1000s of druggable intracellular pockets in primary human cells, finding the targets that actually move disease biology. Our screens also deliver exactly what novel targets have always lacked: rich, target-specific binding and structure-activity data that turns uncharted pockets into actionable chemistry programs.
NEWS
We are hiring scientists!
RIME selected as recipient of AbbVie Biotech Innovators Award
RIME launches with founding financing led by Amplitude Ventures
RIME named to the 2025 cohort of the Merck Digital Sciences Studio
OUR TEAM
Madison Bolger-Munro
Corporate Strategy
Laura DiGiovanni
Platform Innovation
Jean-Christophe Lachance
Computational Biology
Riccardo Cardilli
Head of Finance
Norman Davey
Scientific Co-Founder
Philip Kim
Scientific Co-Founder
BOARD OF DIRECTORS
Michael Mee
CEO
Dion Madsen
Amplitude Ventures
Evelyn Pau
Amplitude Ventures
GET IN TOUCH
Whether you’re interested in partnering, joining the team, or learning more about our approach, we’d love to hear from you.
Montréal, Quebec, Canada